• TransCode Therapeutics amended a May 22 Form 8-K to add details on its plan to regain Nasdaq minimum stockholders’ equity compliance.
• Nasdaq flagged non-compliance with Listing Rule 5550(b)(1) on May 19, requiring at least $2.5 million of stockholders’ equity.
• Its March 31, 2026, Form 10-Q reported stockholders’ equity of $1,251,427.
• Compliance plan centers on stockholder approval to convert Series A Non-Voting Convertible Preferred Stock, enabling reclassification from temporary equity to equity.
• Company has until July 3, 2026, to submit the plan; Nasdaq may grant up to a 180-day extension to regain compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-065959), on May 26, 2026, and is solely responsible for the information contained therein.